The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: a systematic review and network meta-analysis
R Chen, Y Xiong, Y Zeng, X Wang, Y Xiao… - Frontiers in Public …, 2023 - frontiersin.org
Background Hepatitis C virus (HCV) infection is an independent risk factor associated with
adverse outcomes in patients with end-stage renal disease (ESRD). Due to the wide variety …
adverse outcomes in patients with end-stage renal disease (ESRD). Due to the wide variety …
Rescue use of pegylated interferon in dialysis patient who failed to respond sofosbuvir
H Katiyar, P Tiwari, DS Bhadauria, P Rai… - Indian Journal of …, 2023 - journals.lww.com
HCV is treated with sofosbuvir-containing regimens, which are safe, effective, require
negligible monitoring, and have minimal adverse effects. Sofosbuvir is metabolized in the …
negligible monitoring, and have minimal adverse effects. Sofosbuvir is metabolized in the …
Terapi Kombinasi Sofosbuvir dan Daclatasvir Pada Pasien dengan Hepatitis C Kronik: Sebuah Tinjauan Literatur
SA Susilo, HO Saint, AH Saputra… - Health Information …, 2023 - myjurnal.poltekkes-kdi.ac.id
Abstrak Latar Belakang: Hepatitis C kronik merupakan penyakit hati yang disebabkan oleh
virus hepatitis c/HCV. World Health Organization/WHO melaporkan bahwa lebih dari 3 …
virus hepatitis c/HCV. World Health Organization/WHO melaporkan bahwa lebih dari 3 …
Clinical profile and response to treatment in chronic hepatitis C and renal disease: A prospective study from North India
A Ashraf, AY Wajeed, J Khan, AH Shah… - Journal of Integrative …, 2023 - journals.lww.com
MATERIALS AND METHODS: The study was conducted in our hospital, Sher I Kashmir
Institute of Medical Sciences Soura. Patients with HCV infection (detectable RNA levels) with …
Institute of Medical Sciences Soura. Patients with HCV infection (detectable RNA levels) with …